Lexicon Pharmaceuticals Announces Executive Leadership Changes
Company Announcements

Lexicon Pharmaceuticals Announces Executive Leadership Changes

Lexicon Pharmaceuticals ( (LXRX) ) has shared an announcement.

Jeffrey L. Wade, the president and chief operating officer of the company, will be leaving his position on September 30, 2024. He will receive a year’s salary continuation, a substantial lump sum, and COBRA payments for health benefits, along with executive outplacement services. Additionally, he’s signed a consulting agreement for eight months post-termination at a monthly fee. Following Wade’s departure, Kristen L. Alexander, with extensive experience in finance and accounting, will step in as the principal financial officer.

For an in-depth examination of LXRX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyLexicon announces JASN publishes sotagliflozin data
TheFlyLexicon to present data from two studies related to LX9851
Carrie WilliamsLXRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App